Print ISSN:-XXXX

Online ISSN:-XXXX

Issue

Year 2021

Volume: 4 , Issue: 4

Article Access statistics

Viewed: 1385

Emailed: 0

PDF Downloaded: 678

IP Journal of Urology, Nephrology and Hepatology Science


Clinical profile and short term out comes in patients of IgA nephropathy


Full Text PDF Share on Facebook Share on Twitter


Original Article

Author Details : Sreedhara C. G., Umesh L, Anil Mudda, Mahesha V

Volume : 1, Issue : 1, Year : 2018

Article Page : 1-5



Suggest article by email


Abstract

The long-term outcome of patients with ‘IgA’ nephropathy needs to be studied including the clinical spectrum and outcome. We studied 50 patients with biopsy-proven ‘IgA’ nephropathy (IF 2+) who had urinary abnormalities at the time of presentation, we attempt to optimize the clinical spectrum of the patients with ‘IgA’ nephropathy and analyze the short term outcome of the patients including progression to ‘ESRD’. The mean age of the patient was 45.63±3.56 years (IQR 32-48 years) odd ratio was 4.86 years. Majority of the patients were in third decade with male preponderance p=0.023 statistically significant with age group of the population. Renal biopsy showed focal and diffuse mesangio proliferative glomerulonephritis in (22%) and (8%) respectively. Chronic glomerulosclerosis was seen in (58%).Cresentric GN in (28%). IFTA >50% was seen in 44% of patients. ‘IgAN’ is a very common primary glomerulopathy conventionally described as a slowly progressive disease eventually leading to ‘ESRD’ in 30–40% patients. However, it manifests more aggressively in Indian patients with a 10-year renal survival of only 35%, which is lower than the other studies.

Keywords:IgA nephropathy, ESRD, CKD: Chronic Kidney Disease


How to cite : Sreedhara C. G., Umesh L, Mudda A, Mahesha V, Clinical profile and short term out comes in patients of IgA nephropathy. J Urol Nephrol Hepatol Sci 2018;1(1):1-5

Copyright © 2018 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)